Andrew Hollman Meyer Sells 13,334 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Janux Therapeutics Stock Performance

Shares of Janux Therapeutics stock traded up $0.68 on Friday, hitting $53.92. The company had a trading volume of 662,337 shares, compared to its average volume of 802,119. Janux Therapeutics, Inc. has a 1 year low of $7.79 and a 1 year high of $71.71. The stock has a 50 day moving average of $54.52 and a 200-day moving average of $47.73. The stock has a market capitalization of $2.83 billion, a price-to-earnings ratio of -46.09 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics’s quarterly revenue was down 82.6% on a year-over-year basis. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

JANX has been the subject of several recent analyst reports. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research report on Friday, December 27th. Leerink Partnrs upgraded shares of Janux Therapeutics to a “strong-buy” rating in a report on Friday, November 22nd. Scotiabank upped their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the company a “sector perform” rating in a report on Wednesday, December 4th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research note on Tuesday, December 3rd. Finally, BTIG Research boosted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $89.90.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in Janux Therapeutics by 136.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock valued at $4,818,000 after buying an additional 66,340 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Janux Therapeutics during the second quarter valued at approximately $151,000. Principal Financial Group Inc. bought a new stake in Janux Therapeutics during the second quarter worth $237,000. Rhumbline Advisers boosted its position in Janux Therapeutics by 41.2% in the second quarter. Rhumbline Advisers now owns 38,008 shares of the company’s stock worth $1,592,000 after purchasing an additional 11,085 shares during the last quarter. Finally, TD Asset Management Inc bought a new position in Janux Therapeutics in the 2nd quarter valued at $829,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.